… , should the nirmatrelvir plus ritonavir be accessible and clinically appropriate. This study
shows real-world effectiveness of oral antivirals in reducing the mortality risk of community-…

… efficacy, our findings give support to current guidelines prioritizing nirmatrelvir/ritonavir use
over molnupiravir … Amid a pandemic wave of the Omicron variant, real-world effectiveness of …

… recipients had a reduced risk for death (HR:0.34) and hospitalization (HR: 0.76), with mortality
risks to be consistently lower among elderly patients with early antiviral use [20]. In a study …

… trials and real-world studies investigating the efficacy of these … and real-world studies
have demonstrated the efficacy of … mortality, as demonstrated using clinical trials and real-world …

… use showed substantial clinical benefit, including a lower risk of all-cause mortality, in-…
should compare the effectiveness and safety of nirmatrelvir-ritonavir and molnupiravir. This …

… plus ritonavir), whereas the effect on mortality was not … for molnupiravir, and not evaluable
for nirmatrelvir plus ritonavir … the efficacy of both antivirals in preventing all-cause mortality was …

… recipients exhibited a reduced risk of death (HR, 0.34) and hospitalization (HR, 0.76), with
mortality risks that were consistently lower among elderly patients and in response to early …

… hospitalization and mortality by 89… Real-world studies have also suggested the benefits of
MOV and NMV-r. Early initiation of oral antivirals was associated with reduced risks of mortality …

… molnupiravir or nirmatrelvir–ritonavir, this study aimed to assess the effectiveness of both
drugs in reducing mortality and … the real-world effectiveness of molnupiravir and nirmatrelvir–…

… their efficacy, such as molnupiravir and nirmatrelvir/ritonavir, … Treatment with
nirmatrelvir/ritonavir reduced the mortality or … Subtype analysis indicated an 88% reduction in …